UnknownPhase 2

Autologous Platelet-Rich Plasma (PRP) and Endometrial Thickness

Italy200 participantsStarted 2017-02-27

Plain-language summary

The goal of this interventional study is to evaluate the increasing in endometrial thickening after the intrauterine infusion of 0,5-1 ml of autologous Platelet-Rich Plasma (PRP) and the implantation rate in women with thin endometrium undergoing Embryo-transfer, in order to propose a novel therapeutic approach for women with an endometrium \< 7 mm unresponsive to standard treatments.

Who can participate

Age range18 Years – 46 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Endometrial thickness \< 7 mm under estrogen replacement therapy or repeated implantation failure * Age between 18 and 46 years Exclusion Criteria: * Age \< 18 and \> 46 years * Pregnancy * Bleeding diathesis * Previous uterine surgery (miomectomy, cesarean section, etc...) * Platelet count \< 105/μL * Hemoglobin \< 10 g/dL * Presence of a tumor in the wound bed or metastatic disease * Current diagnosis of cancer * Other concomitant active infections

What they're measuring

Endometrial thickness

Timeframe: 24-48h after the intrauterine PRP infusion

Trial details

NCT IDNCT03067623

SponsorUniversity Magna Graecia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-12-31

Contact for this trial

Roberta Venturella, MD

+390961883234 venturella@unicz.it

View on ClinicalTrials.gov More Thin Endometrium trials